New study aims to find best Long-Term insulin plan after intensive therapy for type 2 diabetes
NCT ID NCT07173712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study enrolls 324 adults with type 2 diabetes whose blood sugar is not well controlled on oral medications. All participants will first receive short-term intensive insulin therapy in the hospital. Then, they will be randomly assigned to one of three insulin-based regimens for 24 weeks: a combination insulin and GLP-1 drug, a mixed insulin, or long-acting insulin plus metformin. The goal is to see which approach best helps patients achieve and maintain healthy blood sugar levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Insulin glargine/lixisenatide, insulin degludec/aspart, insulin glargine U300, and metformin
What this could lead to
If successful, this study could identify a simple and effective long-term treatment plan after short-term intensive insulin therapy for people with type 2 diabetes who are not well controlled on oral medications.
What could go wrong
This is a phase 4 trial, so the drugs are already approved, but the best follow-up regimen is unknown. Results may not apply to all patients, and side effects like hypoglycemia or weight gain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.